AU2021301947A1 - Drug for treating tumor - Google Patents

Drug for treating tumor Download PDF

Info

Publication number
AU2021301947A1
AU2021301947A1 AU2021301947A AU2021301947A AU2021301947A1 AU 2021301947 A1 AU2021301947 A1 AU 2021301947A1 AU 2021301947 A AU2021301947 A AU 2021301947A AU 2021301947 A AU2021301947 A AU 2021301947A AU 2021301947 A1 AU2021301947 A1 AU 2021301947A1
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021301947A
Other languages
English (en)
Inventor
Jie Chen
Kun Li
Nan Su
Rongliang WANG
Xunqiang WANG
Ding YU
Xiquan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of AU2021301947A1 publication Critical patent/AU2021301947A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021301947A 2020-06-30 2021-06-30 Drug for treating tumor Pending AU2021301947A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202010619111.6 2020-06-30
CN202010620778 2020-06-30
CN202010619083.8 2020-06-30
CN202010619083 2020-06-30
CN202010620778.8 2020-06-30
CN202010619111 2020-06-30
PCT/CN2021/103687 WO2022002153A1 (zh) 2020-06-30 2021-06-30 用于治疗肿瘤的药物

Publications (1)

Publication Number Publication Date
AU2021301947A1 true AU2021301947A1 (en) 2023-02-16

Family

ID=79317451

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021301947A Pending AU2021301947A1 (en) 2020-06-30 2021-06-30 Drug for treating tumor

Country Status (7)

Country Link
US (1) US20230310596A1 (https=)
EP (1) EP4174087A4 (https=)
JP (1) JP7799638B2 (https=)
CN (1) CN115698076A (https=)
AU (1) AU2021301947A1 (https=)
CA (1) CA3188017A1 (https=)
WO (1) WO2022002153A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116209443A (zh) * 2021-08-05 2023-06-02 正大天晴药业集团股份有限公司 治疗小细胞肺癌的药物组合
CN119278053A (zh) * 2022-06-02 2025-01-07 正大天晴药业集团股份有限公司 用于治疗子宫恶性肿瘤的药物组合

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10435470B2 (en) * 2014-08-05 2019-10-08 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
US9751859B2 (en) * 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
US11001631B2 (en) * 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
CN107460221B (zh) * 2016-06-02 2021-01-15 正大天晴药业集团股份有限公司 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
CN110573172A (zh) * 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
EP3577133A1 (en) * 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
US20210147547A1 (en) * 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN113861295B (zh) * 2018-07-20 2024-05-24 厦门大学 抗pd-1抗体及其用途
AU2020212767B2 (en) * 2019-01-25 2025-01-30 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combined pharmaceutical composition for treating tumor
CN112168961A (zh) * 2019-07-03 2021-01-05 正大天晴药业集团南京顺欣制药有限公司 治疗结直肠癌的联用药物组合物

Also Published As

Publication number Publication date
EP4174087A4 (en) 2024-08-07
EP4174087A1 (en) 2023-05-03
CA3188017A1 (en) 2022-01-06
CN115698076A (zh) 2023-02-03
US20230310596A1 (en) 2023-10-05
JP7799638B2 (ja) 2026-01-21
WO2022002153A1 (zh) 2022-01-06
JP2023531090A (ja) 2023-07-20

Similar Documents

Publication Publication Date Title
US12421313B2 (en) Combined pharmaceutical composition for treating tumor
US12527784B2 (en) Combined pharmaceutical composition for treating small cell lung cancer
EP4442710A1 (en) Drug combination for treating non-small cell lung cancer
CN116370641A (zh) 用于治疗消化系统恶性肿瘤的联用药物
JP7799638B2 (ja) 腫瘍を治療するための薬物
AU2021262368A1 (en) Combination drug for treating kidney cancer
CN113018429A (zh) 治疗卵巢癌的药物组合
US20240343807A1 (en) Pharmaceutical composition for treating small cell lung cancer
EP4197554A1 (en) Combined medication for treating soft tissue sarcoma
RU2859366C2 (ru) Препарат для лечения опухоли
CN119278053A (zh) 用于治疗子宫恶性肿瘤的药物组合
HK40093427A (en) Drug for treating tumor
US20240316031A1 (en) Combination drug for treatment of gastric carcinoma and/or esophagogastric junction cancer
HK40118252A (en) Drug combination for treating non-small cell lung cancer
CN117642181A (zh) 用于治疗食管癌的药物组合
HK40085501A (en) Combination drug for treating kidney cancer
HK40083393A (en) Combination drug for treating kidney cancer
HK40110592A (en) Pharmaceutical composition for treating small cell lung cancer
CN119053623A (zh) 用抗btla作为单一疗法或组合疗法治疗实体瘤的组合物和方法
CN116036265A (zh) 用于癌症的联用药物